Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat mesylate for acute thoracolumbar spinal cord injury
ChiCTR1800015713Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Nafabelltan in spinal cord injury (SCI) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: ASIA spinal cord injury score, IANR spinal cord injury function evaluation scale and 4 more. Started Oct 2017; status: recruiting.
02
Drugs
Nafabelltan
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on ChiCTR1800015713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015713.